Promising Clinical Data On Gen-Probe’s APTIMA(R) HPV Test Presented At Major European Medical Meeting

Gen-Probe’s (Nasdaq: GPRO) CE-marked APTIMA(R) HPV assay may be an important new molecular tool to more accurately detect high-risk human papillomavirus (HPV) infections that are associated with cervical cancer or precancerous lesions, according to nine oral presentations and two scie

More: continued here

Filed under: Cervical Cancer on November 25th, 2008